Novartis nabs two key approvals for Cosentyx to widen its lead on psoriasis rivals

Novartis ($NVS) has been working hard to snap up additional approvals for Cosentyx before its Big Pharma rivals get their next-gen psoriasis contenders to market. And as of Friday, it's done just that in the U.S., where the FDA approved the med as a treatment for psoriatic arthritis and ankylosing spondylitis. With three approvals under its belt, the med could reach peak sales of between $4 billion and $5 billion, Novartis Pharma's global head of development, Vas Narasimhan, said over the summer. More from FiercePharma

Suggested Articles

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.

The FDA wants to know what, exactly, is in a drug name—and whether it influences how the product is perceived. So it's launching a study to find out.

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.